Because of your generosity and goodwill
NSCF has wonderful news to share with our donors and friends. Because of your generosity and goodwill over the last several years, the NSCF has helped move clinical trial collaborations forward into success that has attracted a significant commercial partner.
This afternoon, the University of Louisville announced the commercialization of research NSCF has supported since 2005. There is a short period of time – when research moves from the laboratory into the clinic – when funding is critical and the need is great. That critical gap has been bridged by your contributions to NSCF. You can read the complete news release from the University of Louisville here.
The list of diseases and conditions that will benefit from therapies developed through this commercial partnership is long. Many of them affect you or those you love. Accelerating the development and availability of these stem cell therapies has the potential to shave millions of dollars from current healthcare costs by reducing or eliminating the need for medication and improving the lives and health of the many who will benefit.
Moving this science forward to commercial availability would not have been possible without your help. Thank you for trusting the National Stem Cell Foundation to be good stewards of your funds – and for your continued support.
Building resources for studying Parkinson’s disease
The New York Stem Cell Foundation (NYSCF) Research Institute has entered into a partnership with the Parkinson’s Progression Markers Initiative (PPMI) to build resources for studying Parkinson’s disease to accelerate new treatments. Sponsored by The Michael J. Fox Foundation for Parkinson’s Research, PPMI is a landmark effort to identify and validate biomarkers of Parkinson’s disease. The study is currently under way at 32 clinical sites worldwide with funding from 13 industry partners.
Screening for rare disorders can save lives
When Trevor and Tyler were born in November 2008, Nicole and Steve Aldrian had no reason to suspect anything was wrong with either of their twin sons. Trevor was the first to hold up his head and mimic Mommy’s voice. Soon, though, he began having trouble with feedings. By the time he was four months old, he was vomiting, fussy, and stiff.“He screamed every time he saw the bottle,” says Nicole. Doctors attributed his symptoms to colic, indigestion, and acid reflux. Finally, at six months old, Trevor was diagnosed with Krabbe disease, one of a group of rare genetic disorders called lysosomal storage diseases; others include Pompe disease, Hunter syndrome, and Gaucher’s disease. They are the result of an enzyme deficiency that causes the buildup of unwanted material in the cell’s recycling center, called the lysosome.Babies with Krabbe disease lack the enzyme galactocerebrosidase, which is needed to protect nerve fibers.
Without a stem cell transplant during the first weeks of life, the infantile-onset form of Krabbe disease is fatal. Most infants who have it don’t survive to their second birthday. But the trajectory of these young lives could be dramatically different with a $1 test performed at birth.